Active Ingredient History

  • Now
Ribavirin elaidate (CP-4033; TRX-201), a Lipid Vector Technology derivative of ribavirin. It inhibits elongation factor F4E (elF4E), which stimulates cell growth. Translational Therapeutics Inc. received orphan drug status from the U.S. Food and Drug Administration (FDA) in 2011 for ribavirin elaidate in the treatment of aggressive follicular, medullary and anaplastic thyroid carcinoma.   NCATS

  • Mol. Mass: 508.6508
  • ALogP: -3.01
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)


$8.3361 - $12.5039

United States

$4832.2500 - $8780.3375
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide | 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamidine | 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide | copegus | rbv | rebetol | ribamide | ribamidil | ribamidine | ribapak | ribasphere | ribavarin | ribavirin | ribavirina | ribavirin amidine | ribavirine | ribavirinum | ribofluranosyl carboxamide | tcnr | tribavirin | viramid | virazid | virazole


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue